Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life

OBJECTIVE: The aim of this study was to determine if direct-acting antiviral (DAA) treatment with daclatasvir (DCV) plus asunaprevir (ASV) for 24 weeks influenced the health-related quality of life (HRQOL) at 12 and 24 weeks after treatment initiation [end of treatment (EOT)]. METHODS: This was a pr...

全面介紹

Na minha lista:
書目詳細資料
發表在:Intern Med
Main Authors: Kawakubo, Megumi, Eguchi, Yuichiro, Okada, Michiaki, Iwane, Shinji, Oeda, Satoshi, Otsuka, Taiga, Nakashita, Syunya, Araki, Norimasa, Koga, Akemi
格式: Artigo
語言:Inglês
出版: The Japanese Society of Internal Medicine 2018
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6096027/
https://ncbi.nlm.nih.gov/pubmed/29526929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.0091-17
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍